Coleen Hall

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

Christophe Hézode, Tarik Asselah, K. Rajender Reddy et al. · The Lancet · 2015 · 258 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label results

Hubert H. Fernandez, David G. Standaert, Robert A. Hauser et al. · Movement Disorders · 2014 · 239 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients

John T. Slevin, Hubert H. Fernandez, Cindy Zadikoff et al. · Journal of Parkinson s Disease · 2015 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease

Hubert H. Fernandez, James T. Boyd, Victor S.C. Fung et al. · Movement Disorders · 2018 · 94 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

<scp>E</scp>ffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced <scp>P</scp>arkinson's disease patients

Angelo Antonini, Victor S.C. Fung, James T. Boyd et al. · Movement Disorders · 2016 · 87 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9